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80S Abstracts June Supplement 2014Conclusions: Based on our experiences, the fre-
quency of recanalization after endovenous ablation while
on warfarin is not worse compared with that described in
the literature. The population size of this subset was
small, but it appears antiplatelet agents also had no sig-
niﬁcant impact on incidence of recanalization. Thus,
we believe it is safe to perform endovenous ablation
on systemically anticoagulated patients with no appre-
ciable negative impact on short-term durability or
effectiveness.
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Hypoxia-Inducible Factor 2a
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Objectives: Hypoxia-inducible factors (HIFs) are
transcription factors that transcribe a spectrum of genes
during hypoxia and other stress conditions. In particular,
the HIF-2a subtype is more stable than HIF-1a in mild
hypoxia and plays an essential role in vascular remodeling
by transcribing angiogenic factors. We previously
observed that silencing of Int6, a hypoxia-independent
regulator of HIF-2a protein, led to neoangiogenesis by
facilitating HIF-2a activity in normoxia. The aim of cur-
rent study was to test the hypothesis that silencing of
Int6 in muscle may enhance the recovery of blood ﬂow
in ischemic limbs.
Methods: We used a small interfering RNA (siRNA)
plasmid designed to inhibit the Int6 gene, and assessed
the inﬂuence of Int6 silencing on the gene and protein
expression of mouse myoblasts quantitative RT-PCR and
Western blotting. In vivo, BALB/c mice were randomized
to treatment and control groups. After unilateral femoral
artery ligation, the Int6 siRNA plasmid was injected into
the muscle near the ligation site. Tissue damage and loss
of limb function were scored for 28 days. Serial measure-
ments of limb perfusion were also obtained by laser
Doppler perfusion imaging. A random siRNA plasmid
was given to the control group.
Results: Silencing of Int6 in cultured myoblasts led to
stabilization of HIF-2a protein, accompanied by upregula-
tion of angiogenic genes, including basic ﬁbroblast growth
factor and platelet-derived growth factor-B compared with
the control (P < .05). In a mouse model of hind limb
ischemia, intramuscular injection of the Int6 siRNA
plasmid signiﬁcantly enhanced perfusion (P < .05 at days
7 and 14) and functional recovery (P < .05 at days 7,
14, and 21) of damaged limbs.Conclusions: Silencing of Int6 in muscle led to
enhanced perfusion and functional recovery in ischemic
limbs. Int6 may serve as a therapeutic target to control
angiogenesis in ischemic diseases.
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Objectives: Mesenchymal stem cells (MSCs) have
been shown to improve regeneration of injured tissues in
vivo. Several in vitro studies and animal models have
demonstrated improvement in MSCs paracrine effects un-
der hypoxic conditions. Moreover, several studies sug-
gested that the pro B-type natriuretic peptide (pro-BNP)
could be involved in the stimulation of postischemic
vascular regeneration. The purpose of this study was to
investigate the effect of critical limb ischemia, in a human
model, on in situ adipose-derived mesenchymal stem cells
(ADMSCs) and to determine whether serum levels of N-
terminal pro-BNP correlate with ADMSCs counts and
associated paracrine effects.
Methods: Lipoaspirate samples of $10 mL were
collected from ischemic limbs (ischemic group) and
compared with control samples (without ischemia).
MSCs were characterized by frequency, viability, differenti-
ation potential, cytokines expression, and cell surface
markers. Serum NT pro-BNP was measured as well.
Results: MSCs counts were ninefold to 10-fold higher
in patients with ischemic limbs (mean 7952 6 542 MSC/
mL) than controls (mean 790 6 65 MSC/mL). Pro-BNP
levels (range, 1878-4757 pg/mL) were approximately
eightfold to 26-fold higher than in age- and sex-matched
controls. Furthermore, there were positive correlations be-
tween pro-BNP levels and MSCs counts in the ischemic
group.
Conclusions: Patients with critical limb ischemia
(CLI) have higher levels of pro-BNP and MSCs counts
than controls. Increased levels of pro-BNP and MSCs
counts can be considered humoral and cellular surrogates
of ischemia and hypoxia in patients with CLI. This sup-
ports recent studies that suggest that the increase produc-
tion of peripheral BNP may be a stem cells-mediated
response to stimulate angiogenesis in the ischemic skeletal
muscles.
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